Bavarian Nordic, Serum Institute Expand Chikungunya Vaccine Partnership
Analysis based on 7 articles · First reported Mar 11, 2026 · Last updated Mar 12, 2026
The expanded partnership between Bavarian Nordic and Serum Institute of India is expected to positively impact the pharmaceutical and biotechnology markets by increasing the global supply of the chikungunya vaccine. This collaboration will enhance vaccine accessibility in low- and middle-income countries, potentially boosting revenues for both companies.
Bavarian Nordic A/S announced an expansion of its strategic partnership with Serum Institute of India Pvt. Ltd. (SII) on March 11, 2026. This agreement includes a contract manufacturing agreement for a full technology transfer of the chikungunya vaccine (CHIKV VLP) manufacturing process from Bavarian Nordic to SII. The goal is to scale capacity for future supply to endemic low- and middle-income countries. This new agreement builds on an existing mpox vaccine license and manufacturing agreement with Serum Institute of India and replaces a previous agreement with Biological E. Limited. Additionally, the expanded collaboration will explore potential future co-development opportunities. The CHIKV VLP vaccine, marketed as Vimkunya, has been approved by the United States===Food and Drug Administration, the European Union===European Commission, and the United Kingdom's Medicines & Healthcare products Regulatory Agency in 2025, with regulatory review ongoing in Switzerland and Canada.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard